Abstract 1673P
Background
Imposter Syndrome (IS) is defined as “the inability to internalize achievement and a tendency to attribute success to external factors such as luck, error, or personal connections. It has been associated with psychological distress, emotional suffering, and significant mental health issues. It has also been associated with Burnout (BO), characterized by the emotional exhaustion of individuals in their careers, depersonalization toward other individuals, and a decrease in the sense of personal accomplishments. The study aimed to evaluate the factors associated with IS and its association with BO in medical oncologists (MOs).
Methods
A cross-sectional study was conducted focusing on the MOs actively working in the field. They were invited to the study via mailing list. The sociodemographic and academic data were collected. The IS scores (ISS) was tested using the Clance imposter phenomenon Scale and BO was tested by using the Maslach burnout inventory. The subscales of BO; emotional exhaustion (EE), depersonalization (DP), and personal accomplishment (PA) were analyzed. The characteristics associated with IS and BO were tested by univariate and multivariate analysis.
Results
In the study, 417 MOs with a median age of 40(29-68) were evaluated. The mean of ISS was 50.8+/-15.3, and 122(29.3%) participants had high ISS. The multivariate analysis revealed that female gender was the only factor associated with high ISS (OR: 1.85, CI95%, 1.1- 2.9, p=0.009). While there was a strong positive correlation between ISS and EE (r=0.54, p<0.001) and DP (r=0.48, p<0.001), a strong and negative correlation was found between ISS and PA score (r= -0.41, p<0.001). In the multivariate analysis; high ISS score was the only statistically significant parameter associated with a high EE score (OR:5.03, CI 95% 3.1-8.0, p<0.001), high DP scores (OR=3.4, CI 95% 1.8- 6.5, p<0.001) and low PA scores. (OR=3.73, CI 95% 1.9- 7.1, p<0.001).
Conclusions
The results of the study indicated that IS is prevalent in MOs. The MOs with IS were more emotionally exhausted and more depersonalized. In addition, they had less feeling of personal accomplishment. The IS and its consequences on MOs should be further studied and the strategies to cope with IS should be developed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1709P - Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study
Presenter: Deepak Kilari
Session: Poster session 11
1710P - Exposure-response (E/R) relationship of nivolumab (N) and ipilimumab (I) in patients (pts) with metastatic renal cell clear cell carcinoma (mRCC) from the randomised phase II BIONIKK study
Presenter: Benoit Blanchet
Session: Poster session 11
1711P - Real-word data challenging the treatment paradigm in metastatic renal cancer: Time to separate IMDC intermediate / poor risk groups?
Presenter: John McGrane
Session: Poster session 11
1712P - Real-world efficacy of first-line nivolumab plus ipilimumab and its practical predictive biomarkers in advanced renal cell carcinoma: First analysis from RENOIR study [KCSG GU22-13]
Presenter: Jwa Hoon Kim
Session: Poster session 11
1713P - A deep learning approach utilizing the electronic health record (EHR) to identify cancer recurrence in renal cell carcinoma (RCC)
Presenter: Jue Hou
Session: Poster session 11
1714P - Detection and monitoring of translocation renal cell carcinoma via epigenomic profiling of cell-free DNA
Presenter: Simon Garinet
Session: Poster session 11
1715P - Interim analysis results from a phase II study of adjuvant penpulimab in very high-risk clear cell renal cell carcinoma
Presenter: Xu Zhang
Session: Poster session 11
1716P - Primary resistance to front-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1)
Presenter: martina catalano
Session: Poster session 11